Adenosine A$_{2A}$R blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure

Maria H. Madeira$^{1,2}$, Filipe Elvas$^1$, Raquel Boia$^{1,2}$, Francisco Q. Gonçalves$^{2,4}$, Rodrigo A. Cunha$^{2,4,5}$, António Francisco Ambrósio$^{1,2,3}$ and Ana Raquel Santiago$^{1,2,3,5,*}$

Abstract

**Background:** Elevated intraocular pressure (IOP) is a major risk factor for glaucoma, a degenerative disease characterized by the loss of retinal ganglion cells (RGCs). There is clinical and experimental evidence that neuroinflammation is involved in the pathogenesis of glaucoma. Since the blockade of adenosine A$_{2A}$ receptor (A$_{2A}$R) confers robust neuroprotection and controls microglia reactivity in the brain, we now investigated the ability of A$_{2A}$R blockade to control the reactivity of microglia and neuroinflammation as well as RGC loss in retinal organotypic cultures exposed to elevated hydrostatic pressure (EHP) or lipopolysaccharide (LPS).

**Methods:** Retinal organotypic cultures were either incubated with LPS (3 $\mu$g/mL), to elicit a pro-inflammatory response, or exposed to EHP (+70 mmHg), to mimic increased IOP, for 4 or 24 h, in the presence or absence of the A$_{2A}$R antagonist SCH 58261 (50 nM). A$_{2A}$R expression, microglial reactivity and neuroinflammatory response were evaluated by immunohistochemistry, quantitative PCR (qPCR) and enzyme-linked immunosorbent assay (ELISA). RGC loss was assessed by immunohistochemistry. In order to investigate the contribution of pro-inflammatory mediators to RGC loss, the organotypic retinal cultures were incubated with rabbit anti-tumour necrosis factor (TNF) (2 $\mu$g/mL) and goat anti-interleukin-1$\beta$ (IL-1$\beta$) (1 $\mu$g/mL) antibodies.

**Results:** We report that the A$_{2A}$R antagonist (SCH 58261) prevented microglia reactivity, increase in pro-inflammatory mediators as well as RGC loss upon exposure to either LPS or EHP. Additionally, neutralization of TNF and IL-1$\beta$ prevented RGC loss induced by LPS or EHP.

**Conclusions:** This work demonstrates that A$_{2A}$R blockade confers neuroprotection to RGCs by controlling microglia-mediated retinal neuroinflammation and prompts the hypothesis that A$_{2A}$R antagonists may be a novel therapeutic option to manage glaucomatous disorders.

**Keywords:** Microglia, Adenosine, Neuroprotection, Glaucoma

Background

Glaucoma is the third leading cause of visual impairment and the second cause of blindness worldwide [1]. It is defined as a group of chronic degenerative optic neuropathies, characterized by the irreversible and progressive loss of retinal ganglion cells (RGCs) and damage of the optic nerve (RGC axons). Although glaucoma is a multifactorial disease, elevated intraocular pressure (IOP) is a major risk factor and the current treatments are mainly focused on reducing IOP [2]. However, many patients continue to lose vision despite the control of IOP, and neuroprotective strategies aimed to prevent RGC loss are necessary [3].

Increasing evidence has shown that neuroinflammation has an important role in the pathogenesis of glaucoma [4–6]. Accordingly, microglial cells display an activated amoeboid-like morphology at the early stages of glaucoma [7–10]. In parallel, there is an increased expression and release of pro-inflammatory cytokines [e.g. tumour necrosis
factor (TNF), interleukin-1β (IL-1β)] and nitric oxide (NO) in the glaucomatous eye [11–14]. The importance of this microglia-associated neuroinflammation in glaucoma is underscored by the observation that the control of microglia activation [15–17] or of pro-inflammatory cytokine expression [4, 18] can prevent the loss of RGC in animal models of glaucoma. Microglia-associated neuroinflammation is also involved in different brain disorders [19]. Adenosine is a neuromodulator, which can control inflammatory reactions [20, 21] and microglia reactivity [22–24] mainly through the activation of its G-protein-coupled receptor of the A2A receptor (A2A,R) subtype [25]. Accordingly, A2A,R antagonists afford robust neuroprotection upon ischemia, epilepsy or Alzheimer’s or Parkinson’s disease [25]. All these evidence prompt the hypothesis that A2A,R antagonists may also control the microglia-associated neuroinflammation and loss of RGC in animal models of glaucoma. Therefore, the main aim of this work was to investigate whether A2A,R blockade modulates retinal microglia reactivity, neuroinflammation and loss of RGC triggered by lipopolysaccharide (LPS) or elevated hydrostatic pressure (EHP).

Materials and methods

Animals

Adult Wistar rats were housed in certified local facilities, in a temperature- and humidity-controlled environment, and were provided with standard rodent diet and water ad libitum, under a 12 h light/12 h dark cycle. All procedures involving animals were approved by the Ethical Committee of the Faculty of Medicine of the University of Coimbra/Center for Neuroscience and Cell Biology and are in agreement with the Association for Research in Vision and Ophthalmology statement for animal use.

Organotypic retinal cultures

Wistar rats (8–10 weeks old) were euthanized and their eyes enucleated. Retinas were dissected in a Ca²⁺- and Mg²⁺-free Hank’s balanced salt solution (HBSS (in mM) 137 NaCl, 5.4 KCl, 0.45 KH₂PO₄, 0.34 Na₂HPO₄, 4 NaHCO₃, 5 glucose; pH 7.4) and placed in tissue culture inserts (Millipore; 0.4-μm pore diameter) with the ganglion cell layer (GCL) facing up. The retinas were cultured for 4 days in DMEM-F12 with GlutaMAX I, supplemented with 10% heat-inactivated foetal bovine serum and 0.1% gentamicin (all from Life Technologies) at 37 °C, in 5% CO₂ humidified atmosphere, as previously described [26]. The culture medium was replaced at culture days 1 and 2.

Culture treatments

Organotypic retinal cultures were either incubated with LPS (3 μg/mL, Sigma-Aldrich) or exposed to EHP (70 mmHg above atmospheric pressure) for 4 or 24 h. The concentration of LPS was chosen amongst three tested concentrations of LPS (1, 3 and 5 μg/mL), as the lowest triggering an increase in iNOS immunoreactivity in the majority of microglial cells in organotypic retinal cultures. For the EHP experiments, we used a custom-made humidified pressure chamber equipped with a pressure gauge and a pressure regulator, which allowed maintaining a constant pressure with an air mixture of 95% air and 5% CO₂, as described previously [27]. The chamber was placed in an oven at 37 °C. The magnitude of pressure elevation (70 mmHg above atmospheric pressure) was chosen in accordance with previous studies [27, 28]. For ambient pressure experiments, the organotypic retinal cultures were kept in a standard 5% CO₂ humidified incubator. The cultures were incubated with a selective A2A,R antagonist (SCH 58261; Tocris Bioscience), tested at a selective and supra-maximal concentration (50 nM) [24], which was added 45 min before exposure to LPS or EHP. To test the role of extracellular adenosine, organotypic cultures were treated with 1 μM adenosine deaminase (ADA; Roche Applied Science) which catalyzes the irreversible deamination of adenosine to inosine. In order to investigate the contribution of pro-inflammatory mediators to RGC loss, the organotypic retinal cultures were incubated with rabbit anti-TNF (2 μg/mL; Peprotech) and goat anti-IL-1β (1 μg/mL; R&D Systems) antibodies, or with corresponding immunoglobulin Gs (IgGs), 45 min before exposure to LPS or EHP for 24 h. Organotypic cultures were also incubated with 20 ng/mL TNF and 10 ng/mL IL-1β (ImmunoTools) to evaluate if TNF and IL-1β, by themselves, lead to RGC loss.

Immunohistochemistry

Organotypic cultures were washed with phosphate-buffered saline (PBS (in mM) 137 NaCl, 2.7 KCl, 10 Na₂HPO₄ and 1.8 KH₂PO₄; pH 7.4) and fixed with ice-cold ethanol for 10 min at 4 °C. After washing in PBS, cultures were blocked and permeabilized with 10% normal goat serum, 3% bovine serum albumin and 0.1% Triton X-100 in PBS, for 1 h, and then incubated with the primary antibody (Table 1) for 48 h at 4 °C. After washing, cultures were incubated overnight with the secondary antibody (Table 1), at 4 °C. Retina cultures were then washed and incubated with 4′,6-diamidino-2-phenylindole (DAPI; 1:1000) for 15 min, to stain nuclei. After washing, the preparations were flat-mounted on slides and coverslipped using Glycergel mounting medium.

Image acquisition and densitometric analysis

The preparations were observed with a confocal microscope (LSM 710, Zeiss) on an Axio Observer Z1 microscope using an EC Plan-Neofluar 40x/1.30 Oil DIC M27.
Table 1 Primary and secondary antibodies used in immunohistochemistry

| Primary antibodies | Supplier | Host | Dilution |
|--------------------|----------|------|----------|
| Anti-α2A R         | Santa Cruz Biotechnology | Goat | 1:100    |
| Anti-CD11b         | AbD Serotec | Mouse | 1:250    |
| Anti-iNOS          | BD Biosciences | Rabbit | 1:200    |
| Anti-Bm3a          | Chemicon | Mouse | 1:500    |

| Secondary antibodies | Supplier | Host | Dilution |
|----------------------|----------|------|----------|
| Alexa Fluor anti-mouse 568 | Life Technologies | Donkey | 1:200    |
| Alexa Fluor anti-goat 488 | Life Technologies | Rabbit | 1:200    |
| Alexa Fluor anti-sabbit 488 | Life Technologies | Goat | 1:200    |

**CTCF** = Integrated density – (area of selected cell × mean fluorescence of background reading)

**Circularity index and skeleton analysis**

Morphological alterations of microglia were estimated as previously described [30] using the confocal images of the retinal organotypic cultures labelled with anti-CD11b. Briefly, the particle measurement feature of ImageJ was used to automatically evaluate the circularity index (CI) of microglia, using the formula CI = 4π(area/perimeter²). A circularity index of 1.0 indicates a perfect circle.

The microglial cell complexity and branch length were assessed by skeleton analysis using ImageJ software, as described previously [31]. Briefly, confocal images were converted to 8-bit format, followed by noise de-speckling to eliminate single-pixel background fluorescence. Then, images were converted to binary images, which were analyzed using AnalyzeSkeleton plugin (http://rsb.info.nih.gov/ij/) to assess the number of microglial cell processes, number of branch endpoints and maximum branch length for each cell. These results were analyzed as average per frame.

**ATP quantification**

The extracellular levels of adenosine triphosphate (ATP) were quantified with a luciferase ATP bioluminescence assay kit (Sigma-Aldrich) as we previously described [32]. Briefly, the supernatants were collected and immediately stored at −80 °C until used. Then, 80 µL of these supernatant were added to a white 96-well plate (designed for bioluminescence) placed in a VICTOR multilabel plate reader (PerkinElmer). The luciferin-luciferase ATP assay mix (40 µL) was automatically loaded in each well, and the luminescence output was converted to ATP concentration by interpolation of a standard curve, which was linear between 2 × 10⁻¹² and 8 × 10⁻⁵ M. ATP concentration was normalized to the total amount of protein of each retina, which was determined by the bicinchoninic acid assay (Pierce Biotechnology).

**NO production assay**

The production of NO was quantified by the Griess reaction method in the supernatants of the culture medium. The culture medium was centrifuged (10,000g for 10 min) and the supernatant stored at −80 °C until use. Then, the supernatant was incubated (1:1) with Griess reagent mixture (1 % sulfanilamide in 5 % phosphoric acid with 0.1 % 1-naphthylethylenediamine) for 30 min at room temperature and in the dark. The optical density was measured at 550 nm using a microplate reader (Synergy HT; Biotek). The nitrite concentration was determined from a sodium nitrite standard curve.

**Quantitative real-time PCR**

Total RNA was extracted using Qiagen RNeasy Mini Kit (Qiagen), according to the instructions provided by the manufacturer. The concentration and purity of total RNA were determined using NanoDrop ND1000 (Thermo Scientifics). Then, 1 µg of total RNA was reverse-transcribed using a NZY First-Strand cDNA Synthesis Kit according to the manufacturer instructions (NZYTech, Portugal). The resultant complementary DNA (cDNA) was treated with RNase-H for 20 min at 37 °C, and a 1:2 dilution was prepared for quantitative PCR (qPCR) analysis. All cDNA samples were stored at −20 °C until further analysis.

Genomic DNA contamination was assessed with a conventional PCR for β-actin using intron-spanning primers (Table 2), described previously [33]. SYBR Green-based real-time qPCR was performed using a StepOnePlus PCR system (Applied Biosystems). The PCR conditions were as follows: iQ™ Universal SYBR® Green Supermix (Bio-Rad), 200 nM primers (Table 2) and 2 µL of 1:2 dilution of cDNA, in a total volume of 20 µL. Cycling conditions were a melting step at 95 °C for 15 s, annealing elongation at 60 °C for 45 s and extension at 72 °C, with 40 cycles. A dissociation curve at the end of the PCR run was performed by ramping the temperature of the sample from 60 to 95 °C, while continuously collecting fluorescence data. Ct values were converted to relative quantification using the 2⁻ΔΔCt method [34]. Three candidate housekeeping genes (hprt, Ywhaz and GAPDH) were evaluated using NormFinder, a Microsoft Excel Add-in [35], and hprt was the most stable gene.
Throughout all experimental conditions and samples, therefore, was used as the housekeeping gene.

Enzyme-linked immunosorbent assay
Culture media was centrifuged (10,000g for 10 min) and the supernatant was collected and stored at −80 °C until use. The levels of TNF and IL-1β in the culture supernatants were quantified by enzyme-linked immunosorbent assay (ELISA), according to the instructions provided by the manufacturer (Peprotech).

Retinal ganglion cell counting
Retinal ganglion cells were identified by immunohistochemistry staining with an antibody anti-Brn3a (RGC marker), and confocal images of the GCL were acquired (as described above). The number of Brn3a-immunoreactive cells per image was counted using ImageJ Cell Counter plugin (http://rsbweb.nih.gov/ij/plugins/cell-counter.html). Results represent the average of Brn3a-immunoreactive cells per image.

Statistical analysis
The results are presented as mean ± standard error of the mean (SEM). The data were analyzed using the non-parametric Kruskal-Wallis test, followed by Dunn’s multiple comparison test, as indicated in the figure legends. The statistical analysis was performed using the Prism 6.0 software for Mac OS X (GraphPad Software, Inc).

Results
The retinal organotypic culture is particularly useful to evaluate molecular and cellular mechanisms in the retina because the retinal structure is maintained [26]. Thus, we used this experimental model to investigate the ability of A2A R to control neuroinflammation and RGC death triggered by LPS or EHP (to mimic an increase in IOP).

LPS and EHP increased the expression of A2A R in retinal microglial cells in the GCL
Since the A2A R modulation system undergoes a gain of function upon noxious brain conditions [25], we first assessed if this also occurred in the retina. Therefore, we investigated if LPS or EHP up-regulated the expression of A2A R and bolstered the source of adenosine responsible for the activation of A2A R, i.e. ATP-derived adenosine [36].

LPS or EHP exposure for 4 h significantly increased A2A R messenger RNA (mRNA) expression in the retina by 5.3- and 6.0-fold (n = 6–10), respectively (Fig. 1a). Accordingly, 4 h after exposure to LPS or EHP, A2A R immunoreactivity increased mainly in CD11b-positive cells in the GCL (Fig. 1b), indicating that A2A R in the GCL are mainly present in microglia.

Extracellular ATP levels in control conditions were 0.6 ± 0.3 pmol/μg protein (n = 8) and significantly increased by 173.8 ± 30 and 215.1 ± 40 % after 24 h of exposure to LPS or EHP (n = 6–8), respectively (Fig. 1c).

A2A R blockade prevented the alterations of microglia morphology triggered by LPS or EHP
Modification of cell morphology is one of the hallmarks of microglia activation and has been widely used to categorize different activation states [19]. As shown in Fig. 2a, under control conditions, microglial cells (i.e. CD11b-positive cells) in the GCL typically presented a ramified morphology [circularity index (CI) 0.110 ± 0.02, n = 7; Fig. 2b], compatible with a surveying phenotype. After 24 h of exposure to LPS or EHP, microglia morphology changed to a more amoeboid-like morphology (CI 0.242 ± 0.014 and 0.182 ± 0.006, respectively; n = 5–8, P < 0.05 vs. control). Incubation with the selective antagonist of A2A R (SCH 58261, 50 nM) prevented the LPS- and EHP-induced alterations of microglia circularity index (n = 5–8) (Fig. 2b). In addition, skeleton morphological analysis was used to further document more subtle morphological changes compatible with microglial activation. Retinal microglia from LPS- and EHP-treated cultures presented a decrease in the number of branches (Fig. 2c), endpoints (Fig. 2d) and maximum branch length (Fig. 2e) compared to the control condition. The blockade of A2A R prevented these alterations, indicating that A2A R blockade blunted LPS- and EHP-induced microglia reactivity.

Blockade of A2A R prevented microglia production of NO
Since the activation of microglial cells leads to the production of pro-inflammatory and cytotoxic factors like NO both in vivo and in vitro [37], we tested if A2A R

Table 2 Primers used in qPCR and RT-PCR

| Gene   | GenBank number | Forward | Reverse | Amplicon size (bp) |
|--------|----------------|---------|---------|-------------------|
| A2A R  | NM_053294      | 5’- GGCTATCTCTGACCAACA - 3’ | 3’- TGACCTGACATCTCTATCT - 5’ | 106 |
| TNF    | NM_012675      | 5’- CCCAATCTGTCTCCTCT - 3’ | 3’- TTCTGAGCATCGTAGTGT - 5’ | 90  |
| IL-1β  | NM_031512      | 5’- ATAGAAGTCAAGACAAAGTG - 3’ | 3’- GACCATGTCTGTCTCTAGT - 5’ | 109 |
| Nos II | NM_012611      | 5’- AGAGACAGAAGTGCCGATC - 3’ | 3’- AGAGATCTCAGTGTCAACATA - 5’ | 96  |
| hprt   | NM_012583      | 5’- ATGGAGGGGATCATACTTGT - 3’ | 3’- ATGTAATCCAGGAGTCAAGCAA - 5’ | 76  |
| actb   | NM_031144      | 5’- GCTCCTCCGTAGCCGAAG - 3’ | 3’- CATCTGCTGGAAGGTTGACA - 5’ | 75  |
could control the up-regulation of inducible nitric oxide synthase (iNOS), which plays a critical role in neuroinflammation by generating high amounts of NO in reactive microglia [38].

As expected, the mRNA expression of iNOS significantly increased by 30.5-fold after 4 h of exposure to LPS \((n = 6)\), and this effect was significantly decreased upon \(\text{A}_2\text{A}R\) blockade \((n = 4)\) (Fig. 3a). The exposure to EHP for 4 h also significantly increased iNOS mRNA expression by 4.6-fold over control \((n = 5)\), and the blockade of \(\text{A}_2\text{A}R\) also significantly prevented this effect \((n = 6)\) (Fig. 3a).

In control conditions, the immunoreactivity of iNOS was barely detected in microglia localized in the GCL (Fig. 3b). Exposure to LPS or EHP for 24 h significantly increased iNOS immunoreactivity mainly in CD11b-immunoreactive cells (Fig. 3b, c), confirming that microglial cells are the main producers of NO under these conditions. This effect was abolished by blockade of \(\text{A}_2\text{A}R\), since iNOS immunoreactivity was similar to control (Fig. 3b, c).

The release of NO was indirectly quantified in the culture medium by Griess reaction 24 h after exposure to LPS or EHP (Fig. 3d). In control conditions, nitrite concentration was 5.64 ± 0.17 \(\mu\text{M}\) \((n = 6)\). LPS or EHP significantly increased nitrite concentration to 149.5 ± 11 and 138 ± 3.5 % of the control, respectively \((n = 4–5)\), and these effects were prevented by \(\text{A}_2\text{A}R\) blockade \((n = 3–4)\) (Fig. 3d).

**\(\text{A}_2\text{A}R\) blockade mitigated the inflammatory response induced by LPS or EHP**

Activation of microglia leads to an increased expression and release of pro-inflammatory cytokines, such as IL-1\(\beta\) and TNF [19]. To further test if \(\text{A}_2\text{A}R\) blockade prevented the LPS- and EHP-induced inflammatory response, we quantified mRNA levels encoding for IL-1\(\beta\) and TNF by qPCR. As shown in Fig. 4a, the exposure of retinal organotypic cultures to LPS or EHP for 4 h significantly increased the transcript levels of IL-1\(\beta\) and TNF \((n = 5)\). Overall, the blockade of \(\text{A}_2\text{A}R\) inhibited the LPS- and EHP-induced increase of IL-1\(\beta\) and TNF mRNA levels \((n = 5–7)\) (Fig. 4a).

We next quantified the levels of IL-1\(\beta\) and TNF in the culture medium by ELISA (Fig. 4b). In control conditions, the concentration of IL-1\(\beta\) in the culture
medium was 67.1 ± 5.5 pg/mL and the concentration of TNF was 30.9 ± 53.7 pg/mL (n = 10–15). Incubation with LPS or EHP for 4 h significantly increased IL-1β concentration in the culture medium to 135.3 ± 6.9 and 146.7 ± 9 pg/mL, respectively (n = 6–8), and the TNF concentration to 317.6 ± 40.6 and 162.8 ± 42.6 pg/mL, respectively (n = 6–9) (Fig. 4b). The blockade of A2AR significantly inhibited the LPS- and the EHP-induced increase of IL-1β or TNF levels in the culture medium (n = 5) (Fig. 4b).

Additionally, we tested if the removal of endogenous extracellular adenosine was equivalent to blocking A2AR in the control of LPS- or EHP-induced neuroinflammation. We found that the pretreatment of organotypic cultures with ADA (1 U/mL), which removes extracellular adenosine, abrogated the LPS- and EHP-induced increase
in the expression (Fig. 4a) and extracellular levels (Fig. 4b) of both TNF and IL-1β (n = 3).

A2AR blockade prevented RGC death through the control of neuroinflammation

The elevation of the hydrostatic pressure is an experimental strategy to mimic in a retina culture model a situation of IOP increase, which is a major risk factor for glaucoma [2]. Studies from Sappington et al. [27] have already described RGC death under EHP conditions.

Since A2AR blockade prevented microglia activation and the expression and release of pro-inflammatory cytokines, we next tested if A2AR blockade also prevented the loss of RGC induced by LPS or EHP in retinal organotypic cultures. Loss of RGCs was evaluated by counting the number of RGC, identified with an antibody

Fig. 3 Blockade of A2AR decreases the expression and immunoreactivity of iNOS and NO production induced by LPS or EHP. Retinal organotypic cultures were pretreated with SCH 58261 (50 nM) and then challenged with LPS (3 μg/mL) or EHP (+70 mmHg) for 4 h. a iNOS mRNA expression was assessed by qPCR. Results are presented as fold change of the control, from six to twelve independent experiments. b Organotypic retinal cultures were immunostained for iNOS (green) and CD11b (microglia marker; red) and imaged in the GCL using a confocal microscope. Nuclei were stained with DAPI (blue). The images are representative of four to five independent experiments. c The immunoreactivity of iNOS in microglia localized in the GCL was quantified. Results are expressed as percentage of control from four to five independent experiments. d The production of NO was assessed by the Griess reaction in the culture supernatants, and nitrite formation was quantified. Results are expressed as percentage of control and are mean ± SEM of four to six independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001, different from control; *P < 0.05, different from LPS; #P < 0.05 and ###P < 0.001, different from EHP; Kruskal-Wallis test, followed by Dunn’s multiple comparison test.
antibodies against TNF and IL-1β before incubation with LPS or exposure to EHP, in order to reduce the levels of both pro-inflammatory cytokines. The incubation of organotypic retinal cultures with antibodies against TNF and IL-1β prior incubation with LPS or exposure to EHP fully prevented the loss of RGCs (180.6 ± 8 and 170.2 ± 4 Brn3a-immunoreactive cells, respectively, n = 5; Fig. 5b, c).

As a control, the incubation with rabbit and goat IgGs did not significantly inhibit the decrease in the number of RGC upon exposure to LPS or EHP (n = 4). In addition, incubation with TNF (20 ng/mL) plus IL-1β (10 ng/mL) was sufficient to induce loss of RGC (n = 3) (Fig. 5c) to an extent similar to that triggered by LPS or EHP. Moreover, incubation with the neutralizing antibodies in control conditions did not alter the number of RGCs present in the culture (data not shown). The neutralizing experiments under noxious conditions (LPS or EHP) fully recapitulated the incubation with SCH 58261, further supporting our conclusion that A2AR blockade control RGC loss through a control of retinal neuroinflammation.

Discussion

The present work demonstrates that the blockade of A2AR prevented retinal neuroinflammation and death of RGC in an ex vivo model of glaucoma. We exposed retinal organotypic cultures to LPS and EHP, which bolstered microglia reactivity, increased neuroinflammatory response and loss of RGCs. These two noxious conditions up-regulated the A2AR system, as typified by an increase in the extracellular levels of ATP and increased expression and density of A2AR in microglia. Concomitantly, the A2AR system critically contributed to the neuroinflammation and RGC death, since A2AR blockade prevented the activation of microglia, the production of pro-inflammatory cytokines and the death of RGCs.

We took advantage of retinal organotypic cultures, a suitable model to evaluate cellular and molecular signaling mechanisms in which retinal anatomy is maintained and which has been established as a convenient model for screening potential neuroprotective drugs in the retina [41]. This in vitro system enabled us to demonstrate that EHP changed microglia morphology towards an ameboid-like form, similar to that caused by LPS, which has been extensively used as a microglial activator. Activation of microglial cells is observed as an early event in animal models of glaucoma [9, 42], in which increased IOP is a main risk factor [2]. In retinal organotypic cultures, the observed EHP- and LPS-induced microglia reactivity was paralleled by an increased expression and release of the pro-inflammatory cytokines IL-1β and TNF. Likewise, an increased production of TNF [11, 43] and IL-1β [44, 45] has been observed in glaucomatous animal models and in human glaucoma. Furthermore, the ability of anti-IL-1β and anti-TNF antibodies to prevent...
EHP-induced RGC death provided critical evidence that the death of RGCs upon exposure to EHP or LPS in retinal organotypic cultures actually resulted from the impact of pro-inflammatory cytokines. This is in agreement with previous reports demonstrating that the control of microglia reactivity [15–17] or of pro-inflammatory cytokines [4, 18, 46] prevents the loss of RGC in animal models of glaucoma. Nevertheless, the release of IL-6 by astrocytes and microglia triggered by EHP was reported to protect RGCs [27], although the authors used purified cultures of microglia, astrocytes and RGCs and did not evaluate the possible interactions between these cells in a more complex in vitro model, as the retinal organotypic culture. The globally deleterious role of microglia-associated pro-inflammatory status is further heralded by the report that minocycline, an inhibitor of microglia activation, reduced microglia activation and improved RGC axonal transport and integrity [15]. Overall, this evidence indicates that microglia reactivity is a precocious event and contributes to the pathophysiology of glaucoma by impairing the viability of RGCs.

The main conclusion of this study was the critical role of A2AR in the control of EHP- or LPS-induced microglia activation, production of pro-inflammatory cytokines and RGC death in retinal organotypic cultures. Indeed, we observed that the blockade of A2AR prevented the EHP- or LPS-induced modification of the production of pro-inflammatory cytokines and of NO as it was previously observed in the rodent hippocampus [24]. Accordingly, it was already demonstrated that
activation of A<sub>2A</sub>R potentiates NO release from reactive microglia in culture, an effect that was associated with microglia neurotoxicity, and A<sub>2A</sub>R antagonist was suggested as a potential neuroprotective drug [22]. Moreover, we observed that A<sub>2A</sub>R blockade prevents EHP-induced microglia morphological alterations, in agreement with recent findings that A<sub>2A</sub>R antagonism reduces the retraction of processes in LPS-activated microglia [47].

These conclusions seems to contradict previous studies reporting that the activation of A<sub>2A</sub>R reduces microglia reactivity using primary retinal microglia cultures exposed either to LPS, hypoxia or amadori-glycated albumin [48–50]. Several factors may explain this discrepancy: (1) while others used cultures of microglial cells, we used an organotypic retinal culture in which all retinal cells are present, and thus, an additional contribution from other glial cells cannot be excluded [51, 52]; this is particularly important given that the control by A<sub>2A</sub>R of microglia reactivity can be shifted from inhibitory to excitatory by the presence of increased extracellular levels of glutamate [53]; (2) the insults triggering microglia activation are different and the LPS concentrations and time points were different; and (3) CGS 21680, the A<sub>2A</sub>R agonist, at the concentration used in those studies (20 and 40 μM) is no longer selective, being proposed to bind also to A<sub>1</sub>R [54, 55]. The A<sub>1</sub>R is coupled to G<sub>160</sub>-proteins and often inhibitory, whereas the A<sub>2A</sub>R is usually coupled to G<sub>ε</sub>-proteins, enhancing cAMP accumulation and PKA activity [56]. Nevertheless, the observation of different responses in different models should be taken into account due to the dual role of adenosine receptors and different responses of microglia, which can be elicited with different stimuli and environmental conditions [57]. In fact, in the brain, it is the blockade rather than the activation of A<sub>2A</sub>R than reduce microglia activation and neuroinflammation upon different noxious stimuli [58, 24]. This probably contributes to the neuroprotection afforded by A<sub>2A</sub>R antagonists in brain diseases with a neuroinflammatory involvoment such as ischemia, epilepsy, traumatic brain injury, multiple sclerosis or Alzheimer’s or Parkinson’s disease (reviewed in [25]). Accordingly, we also observed that A<sub>2A</sub>R blockade prevented the LPS- and the EHP-induced RGC death in retina organotypic cultures. This might result from the ability of A<sub>2A</sub>R to control the activation of microglia and the production of pro-inflammatory cytokines that we showed to be sufficient and necessary to trigger RGC death, but it may also involve an ability of A<sub>2A</sub>R to directly control neuronal viability. In fact, neuronal A<sub>2A</sub>R can directly affect the degeneration of mature neurons upon exposure to different stimuli (e.g. [59, 60]), namely to pro-inflammatory cytokines [61], whereas they have an opposite effect in immature neurons [62, 63] and during neurodevelopment [64].

In our work, the relevance of the A<sub>2A</sub>R modulation system in the control of RGC death through a control of neuroinflammation in the retina is further underscored by the observed up-regulation of this system in retinal organotypic cultures exposed either to LPS or to EHP. In fact, LPS and EHP caused an increase in the extracellular levels of ATP. The cellular source of this extracellular ATP is not clear, but it can be released from different cells in the retina, such as RGCs [65], microglia [66] and Müller cells [67]. Moreover, recent work demonstrated that astrocytes present in the optic nerve head can also release ATP through pannexin channels in response to a mechanical strain, suggesting this mechanism as a source of extracellular ATP under chronic mechanical strain, as occurs in glaucoma [68]. Actually, elevated levels of extracellular ATP have been reported in the retina as a response to an acute rise in ocular pressure [69, 70], and the ATP levels are elevated in the aqueous humour of patients with primary acute and chronic angle closure glaucoma, which presents evidence for a contribution of the purinergic signaling in this disease [71, 72]. The increased levels of ATP can function as a danger signal [73] and can either activate P2 receptors, namely P2X7 receptors in the retina [74, 65, 75, 76], or be extracellular catabolized by ecto-nucleotidases into extracellular adenosine that preferentially activates A<sub>2A</sub>R [77, 36]. Remarkably, EHP and LPS not only bolstered the source of adenosine activating A<sub>2A</sub>R but also triggered an increased expression of A<sub>2A</sub>R, which was translated into an increased density of A<sub>2A</sub>R in microglia. This is in accordance with the up-regulation of A<sub>2A</sub>R that is observed upon different noxious conditions (reviewed in [78, 25]), namely in microglia [79, 24, 80]. Thus, noxious stimuli such as LPS or EHP triggered an up-regulation of the A<sub>2A</sub>R system in retinal microglia, which critically contributes to the development of neuroinflammation and RGC death. We cannot rule out the role of A<sub>2A</sub>R present in other cell types of the retinal organotypic culture, but in the GCL, A<sub>2A</sub>R was found to be mainly located in microglia. Furthermore, additional studies will be required to determine if A<sub>2A</sub>R blockade only affords a prophylactic benefit or may also be therapeutically effective.

**Conclusions**

The present results demonstrate that EHP can lead to an inflammatory response, similar to LPS, which is associated with the death of RGC. Thus, the organotypic retinal culture exposed to EHP may be an important experimental model to investigate neuroprotective and anti-inflammatory pharmacological strategies against RGC death. Herein, we demonstrate for the first time that A<sub>2A</sub>R blockade prevents retinal microglia reactivity and pro-inflammatory responses triggered by LPS or
EHP and confers neuroprotection to RGC by controlling retinal neuroinflammation induced by EHP or LPS. This prompts the hypothesis that A2A\(R\) antagonists might have therapeutic potential in the treatment of glaucoma, a proposal re-enforced by the report that IOP could be reduced by a selective A2A\(R\) antagonist, ZM 241385, in mice [81].

**Abbreviations**

ADA: Adenosine deaminase; ATP: Adenosine triphosphate; A\(2A\) receptor; CTCF: Corrected total cell fluorescence; EHP: Elevated hydrostatic pressure; GCL: Ganglion cell layer; IL: Interleukin; iNOS: Inducible nitric oxide synthase; IOP: Intraocular pressure; LPS: Lipopolysaccharide; NO: Nitric oxide; PBS: Phosphate-buffered saline; RGC: Retinal ganglion cell; TNF: Tumour necrosis factor.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

MMH, RAC, AFA and ARS conceived and designed the experiments: MMH, FE, RB and FQG performed the experiments: MMH, FE, RB, FQG, RAC, AFA and ARS. The authors read and approved the final version of the manuscript.

**Acknowledgments**

We are grateful to Fábio Paiva and to Margarida Souto-Carneiro (Center for Neuroscience and Cell Biology, Coimbra, Portugal) for providing the rabbit and goat IgGs. MH Madeira is a recipient of a PhD fellowship from the Foundation for Science and Technology (FCT, Portugal; SFRH/BD/75839/2011). The work was supported by FCT (PTDC/BCM-MEC/09132/2012, Pest-C/SAU/LA0001/2013-2014 and Pest-C/SAU/UI3282/2011-2013), Portugal, and COMPETE-FEDER (FCOMP-01-0124-FEDER-029417), AIBILI and QREN (CENTRO-07-ST24-FEDER-002006). There is no financial disclosure.

**Author details**

1. Institute for Biomedical Imaging and Life Sciences (IIBIL), Faculty of Medicine, University of Coimbra, 3004-548 Coimbra, Portugal.
2. FCT-IIBIL, University of Coimbra, 3004-517 Coimbra, Portugal.
3. Association for Innovation and Biomedical Research on Light (AIBILI), 3004-548 Coimbra, Portugal.
4. CNC-IIBIL, Faculty of Medicine, University of Coimbra, 3004-548 Coimbra, Portugal.
5. CNC, Faculty of Medicine, University of Coimbra, 3000-496 Coimbra, Portugal.
6. IIBIL, Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3004-548 Coimbra, Portugal.

**Received:** 26 January 2015 **Accepted:** 27 May 2015 **Published online:** 10 June 2015

**References**

1. Resnikoff S, Pascolini D, Etyaale D, Kocur I, Pararajasegaram R, Polkarel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Org. 2004;82:844–51.
2. Caporilli J. Glaucoma: a disease of early cellular senescence. Invest Ophthalmol Vis Sci. 2013;54(14):ORSF60–7. doi:10.1167/iovs.13-12716.
3. Cordeiro MF, Levin LA. Clinical evidence for neuroprotection in glaucoma. Am J Ophthalmol. 2011;152(5):718–6. doi:10.1016/j.ajo.2011.06.015.
4. Howell GR, Macalinao DG, Sousa GL, Walden M, Soto I, Kneeland SC, et al. Neuronal expression in the optic nerve head of the CD200 receptor complex in microglia activation in experimental mouse model of chronic glaucoma. J Neuroimmunol. 2000;103(1-3):127–33. doi:10.1016/S0165-5728(00)00208-9.
5. Krizaj D, Ryskamp DA, Tian N, Tezel G, Mitchell CH, Slepak VZ, et al. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. Invest Ophthalmol Vis Sci. 2008;49(9):4373–8. doi:10.1167/iovs.07-1337.
6. Yang X, Chou TH, Ruggeri M, Porciatti V. A new mouse model of inducible, chronic retinal ganglion cell dysfunction not associated with cell death. Invest Ophthalmol Vis Sci. 2013;54(3):1988–90. doi:10.1167/iovs.12-11375.
7. Wang K, Peng B, Lin B. Fractalkine receptor regulates microglial neurotoxicity in an experimental mouse glaucoma model. Glia. 2014;62(12):1943–54. doi:10.1002/glia.22715.
8. Roh M, Zhang Y, Murakami Y, Thanos A, Lee SC, Vavvas DG, et al. Etanercept, a widely used inhibitor of tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One. 2012;7(7):e40616. doi:10.1371/journal.pone.0040616.
9. rituzumab is a monoclonal antibody that targets CD20 and exerts its anti-proliferative effects on B cells. J Immunother. 2005;28(4):409–21. doi:10.1097/01.jim.0000183764.84035.eb.
10. Moriguchi S, Greco A, Potenza RL, Pezzola A, Blum D, Bantburg K, et al. Effects of the adenosine A\(2A\) receptor antagonist SCH 58261 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration. J Neuropathol Exp Neurol. 2007;66(5):363–71. doi:10.1097/NEN.0b013e31805f477.
11. Rebola N, Smölös AP, Canas PM, Tomé AR, Andrade GM, Barry CE, et al. Adenosine A\(2A\) receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J Neurochem. 2011;117(11):1002–11. doi:10.1111/j.1471-4159.2011.07178.x.
12. Gomes CV, Kaster MP, Tomé AR, Agostinho PM, Cunha RA. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Bioch Biophys Acta. 2011;1808(3):380–99. doi:10.1016/j.bbapap.2010.12.001.
13. Kretz A, Hermering SH, Isenmann S. A novel primary culture technique for rat retinal explants that preserves retinal ganglion cells from pressure-induced death. Invest Ophthalmol Vis Sci. 2008;49(11):4232–42. doi:10.1167/iovs.07-1407.
mechanosensitive upregulation of pannexin channels in optic nerve head astrocytes: a mechanism for purinergic involvement in chronic strain. Glia. 2014;62(9):1486–501. doi:10.1002/glia.22695.

69. Reigada D, Lu W, Zhang M, Mitchell CH. Elevated pressure triggers a physiological release of ATP from the retina: possible role for pannexin hemichannels. Neuroscience. 2008;157(2):396–404. doi:10.1016/j.neuroscience.2008.08.036.

70. Resta V, Novelli E, Vozi G, Scarpa C, Caleo M, Ahluwalia A, et al. Acute retinal ganglion cell injury caused by intraocular pressure spikes is mediated by endogenous extracellular ATP. Eur J Neurosci. 2007;25(9):2741–54. doi:10.1111/j.1460-9568.2007.05528.x.

71. Zhang X, Li A, Ge J, Reigada D, Laties AM, Mitchell CH. Acute increase of intraocular pressure releases ATP into the anterior chamber. Exp Eye Res. 2007;85(S1):e37–43. doi:10.1016/j.exer.2007.07.016.

72. Li A, Zhang X, Zheng D, Ge J, Laties AM, Mitchell CH. Sustained elevation of extracellular ATP in aqueous humor from humans with primary chronic angle-closure glaucoma. Exp Eye Res. 2011;93(4):528–33. doi:10.1016/j.exer.2011.06.020.

73. Rodrigues R, Tomé A, Cunha R. ATP as a multi-target danger signal in the brain. Front Neurosci. 2015;9:148. doi:10.3389/fnins.2015.00148.

74. Hu H, Lu W, Zhang M, Zhang X, Argall AJ, Patel S, et al. Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Exp Eye Res. 2010;91(3):245–52. doi:10.1016/j.exer.2010.06.017.

75. Niyadurupola N, Sidaway P, Ma N, Rhodes JD, Broadway DC, Sanderson J. P2X7 receptor activation mediates retinal ganglion cell death in a human retina model of ischemic neurodegeneration. Invest Ophthalmol Vis Sci. 2013;54(3):2163–70. doi:10.1167/iovs.12-10968.

76. Sugiyama T, Lee SY, Horie T, Oku H, Takai S, Tanicka H, et al. P2X(7) receptor activation may be involved in neuronal loss in the retinal ganglion cell layer after acute elevation of intraocular pressure in rats. Mol Vis. 2013;19:2080–91.

77. Rebola N, Lujan R, Cunha RA, Mulle C. Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron. 2008;57(1):121–34. doi:10.1016/j.neuron.2007.11.023.

78. Cunha RA. Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade. Purinergic Signalling. 2005;1:111–34.

79. Gomes C, Ferreira R, George J, Sanches R, Rodrigues Di, Gonçalves N, et al. Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A2A receptor-dependent manner: A2A receptor blockade prevents BDNF release and proliferation of microglia. J Neuroinflammation. 2013;10(1):16. doi:10.1186/1742-2094-10-16.

80. Santiago AR, Baptista Fl, Santos PF, Cristovao G, Ambrosio AF, Cunha RA, et al. Role of microglia adenosine A2A receptors in retinal and brain neurodegenerative diseases. Mediat Inflamm. 2014;2014:665694. doi:10.1155/2014/665694.

81. Avila MY, Stone RA, Civan MM. A(1), A(2A)- and A(3)-subtypes adenosine receptors modulate intraocular pressure in the mouse. Br J Pharmacol. 2001;134(2):241–5. doi:10.1038/sj.bjp.0704267.